A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with PreviouslyUntreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
Cabozantinib With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Kidney Cancer (COSMIC-313)
Sponsor: Exelixis, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS8482
U.S. Govt. ID: NCT03937219
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study will test whether cabozantinib in combination with nivolumab plus ipilimumab is more effective (works better) than nivolumab plus ipilimumab alone in treating patients with advanced kidney cancer who have not received prior treatment for their cancer. This study will also examine how safe cabozantinib is in combination with nivolumab plus ipilimumab and how well people with advanced kidney cancer who have not received prior treatment tolerate this combination.
This study is closed
Investigator
Mark Stein, MD
Do You Qualify?
Are you at least 18 years of age? Yes No
Do you have advanced metastatic renal cell carcinoma (kidney cancer)? Yes No
Are you able to perform everyday activities independently? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE